Attached files
file | filename |
---|---|
EX-99 - PRESS RELEASE - OWC Pharmaceutical Research Corp. | exh99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): April 4, 2017
OWC
Pharmaceutical Research Corp.
(Exact Name of
Registrant as Specified in its Charter)
Commission File No.: 0-54856
Delaware | 98-0573566 |
(State of Incorporation) | (I.R.S. Employer Identification No.) |
30 Shacham Street. P.O.B. 8324 Petach Tikva, Israel | 4918103 |
(Address of Principal Executive Offices) | (ZIP Code) |
Registrant's Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events. OWC Pharmaceutical Research Corp. ("OWC") is reporting
the issuance on April 5, 2017 of the attached press release, announcing that
as a result of the promising conclusions reported in its Form 8-K filed on
March 20, 2017, the Company has received expressions of scientific and
medical interest, world-wide, for its cannabinoid-based topical cream for
treating psoriasis. OWC has expanded the size and scope of its clinical
studies and, as previously announced, anticipates that subject to pending
regulatory approvals from applicable jurisdictions, the topical cream should
be available for use by those who suffer from psoriasis in the near term. Reference is made to the full text of the press release filed
as Exhibit 99.1 herewith. Item 9.01 Financial Statements and Exhibits. (a) The following documents are filed as exhibits to
this report on Form 8-K or incorporated by reference herein. Any document incorporated by
reference is identified by a parenthetical reference to the SEC filing that included such
document. Exhibit
No.
SIGNATURES Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Description
99.1
Press Release dated April 5, filed herewith.
OWC Pharmaceutical Research Corp. | ||
By: /s/ Mordechai Bignitz | ||
Name: Mordechai Bignitz | ||
Title: Chief Executive Officer |
Date: April 4, 2017